Do inactivating mutations or inhibition of ANGPTL4 reduce triglyceride levels and the risk of coronary artery disease?
Inactivating mutations or inhibition of ANGPTL4 are associated with lower triglycerides and reduced risk of coronary artery disease, suggesting it as a potential therapeutic target for cardiovascular prevention.
Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Dewey et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: